CO2023013445A2 - Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma - Google Patents

Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma

Info

Publication number
CO2023013445A2
CO2023013445A2 CONC2023/0013445A CO2023013445A CO2023013445A2 CO 2023013445 A2 CO2023013445 A2 CO 2023013445A2 CO 2023013445 A CO2023013445 A CO 2023013445A CO 2023013445 A2 CO2023013445 A2 CO 2023013445A2
Authority
CO
Colombia
Prior art keywords
nitrogen oxide
oxide compound
crystal form
pyridine nitrogen
crystalline form
Prior art date
Application number
CONC2023/0013445A
Other languages
English (en)
Inventor
Jianbiao Peng
Yong Zhang
Cheng Cao
Qingwei Wan
Hongming Cheng
Original Assignee
Shanghai Jemincare Pharmaceutical Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceutical Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceutical Co Ltd
Publication of CO2023013445A2 publication Critical patent/CO2023013445A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un forma cristalina de un compuesto de óxido de nitrógeno de piridina y el uso de la misma. Específicamente, la presente invención se refiere a una forma cristalina de un compuesto de fórmula (I), una composición farmacéutica y un uso de la misma.
CONC2023/0013445A 2021-03-11 2023-10-10 Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma CO2023013445A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110265997 2021-03-11
CN202210195905 2022-03-01
PCT/CN2022/080430 WO2022188872A1 (zh) 2021-03-11 2022-03-11 吡啶氮氧化合物晶型及其应用

Publications (1)

Publication Number Publication Date
CO2023013445A2 true CO2023013445A2 (es) 2024-02-15

Family

ID=83226280

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0013445A CO2023013445A2 (es) 2021-03-11 2023-10-10 Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma

Country Status (13)

Country Link
US (1) US20240208908A1 (es)
EP (1) EP4306511A1 (es)
JP (1) JP2024509939A (es)
KR (1) KR20240019064A (es)
CN (1) CN116829539A (es)
AU (1) AU2022233221A1 (es)
BR (1) BR112023018348A2 (es)
CA (1) CA3211594A1 (es)
CL (1) CL2023002687A1 (es)
CO (1) CO2023013445A2 (es)
MX (1) MX2023010704A (es)
TW (1) TW202300147A (es)
WO (1) WO2022188872A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116891432A (zh) * 2022-04-02 2023-10-17 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
TW202348229A (zh) * 2022-06-02 2023-12-16 大陸商上海濟煜醫藥科技有限公司 吡啶氮氧化合物的製備方法
CN117263856A (zh) * 2022-06-22 2023-12-22 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
CA3105657A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
PE20221515A1 (es) * 2019-09-12 2022-10-04 Shanghai Jemincare Pharmaceuticals Co Ltd Oxinitruro de piridina, metodo para su preparacion y uso de este
CN112225695B (zh) * 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途

Also Published As

Publication number Publication date
CL2023002687A1 (es) 2024-03-08
MX2023010704A (es) 2023-12-07
AU2022233221A1 (en) 2023-10-26
KR20240019064A (ko) 2024-02-14
TW202300147A (zh) 2023-01-01
JP2024509939A (ja) 2024-03-05
CA3211594A1 (en) 2022-09-15
BR112023018348A2 (pt) 2023-12-05
CN116829539A (zh) 2023-09-29
EP4306511A1 (en) 2024-01-17
WO2022188872A1 (zh) 2022-09-15
US20240208908A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
CO2023013445A2 (es) Forma cristalina de un compuesto de óxido de nitrógeno de piridina y uso de la misma
CY1122585T1 (el) Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο ηiv
CL2019000477A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino.
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CR20190423A (es) Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
CY1123689T1 (el) Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης
AR084032A1 (es) Compuesto biciclico
CR20170605A (es) DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA
ECSP11010878A (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
UY32490A (es) Inhibidores de beta-secretasa
NO20080761L (no) Acykliske Ikur inhibitorer
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
NI201200146A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
CO6300946A2 (es) Forma cristalina de derivado de fenilamino pirimidina
ECSP23002606A (es) Nuevo inhibidor de la secreción de ácido y uso del mismo
ECSP109919A (es) Compuesto de piridacina cristalina
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
CL2021000421A1 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende.
CO2022010011A2 (es) Derivado de amino arilo novedoso útil como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
CO2024004552A2 (es) Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß